ARDS (Aridis Pharmaceuticals) Total Assets : $6.53 Mil (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aridis Pharmaceuticals Total Assets?

Aridis Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $6.53 Mil.

Total Assets is connected with ROA %. Aridis Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2023 was -5.10%. Total Assets is also linked to Revenue through Asset Turnover. Aridis Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Aridis Pharmaceuticals Total Assets Historical Data

The historical data trend for Aridis Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aridis Pharmaceuticals Total Assets Chart

Aridis Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

31.61

27.97

15.12

26.80

14.70

Aridis Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Assets	Get a 7-Day Free Trial															12.12	14.70	9.43	6.48	6.53

Aridis Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aridis Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	-24.232	+	38.927
	=	14.70

Aridis Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	-11.802	+	18.336
	=	6.53

Aridis Pharmaceuticals (OTCPK:ARDS) Total Assets Explanation

Total Assets is connected with ROA %.

Aridis Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-0.332	/	( (6.482	+	6.534)	/ 2 )
	=	-0.332	/	6.508
	=	-5.10 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aridis Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	0	/	( (6.482	+	6.534)	/ 2 )
=	0	/	6.508
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aridis Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aridis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aridis Pharmaceuticals Inc (OTCPK:ARDS) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

983 University Avenue, Building B, Los Gatos, CA, USA, 95032

Website

https://www.aridispharma.com

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

Executives

Vu Truong	director, 10 percent owner, officer: CEO, CSO, Director	5941 OPTICAL CT., SAN JOSE CA 95138
Eric Patzer	director, 10 percent owner	5941 OPTICAL CT., SAN JOSE CA 95138
Fibrosis Foundation Cystic	10 percent owner	4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814
Hasan Jafri	officer: Chief Medical Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
John F Hamilton	director	1360 O'BRIEN DR, MENLO PARK CA 94025
Michael Adrian Nazak	officer: Chief Financial Officer	5941 OPTICAL COURT, SAN JOSE CA 95138
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Fred Kurland	officer: Chief Financial Officer	C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Wolfgang Dummer	officer: Chief Medical Officer	5491 OPTICAL CT., SAN JOSE CA 95138
Robert R Ruffolo	director
Shawn Lu	director	C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326
Robert K. Coughlin	director	5941 OPTICAL CT., SAN JOSE CA 95138
Craig S Gibbs	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025